Guanfacine
- Generic Name
- Guanfacine
- Brand Names
- Intuniv, Tenex
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3O
- CAS Number
- 29110-47-2
- Unique Ingredient Identifier
- 30OMY4G3MK
- Background
Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.
Guanfacine was granted FDA approval on 27 October 1986.
- Indication
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
- Associated Therapies
- -
Stress and Medication Effects on Cocaine Cue Reactivity
- Conditions
- Interventions
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 109
- Registration Number
- NCT00613015
- Locations
- 🇺🇸
Medical University of South Carolina-GCRC, Charleston, South Carolina, United States
Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse
- Conditions
- Interventions
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Yale University
- Target Recruit Count
- 75
- Registration Number
- NCT00585754
- Locations
- 🇺🇸
Yale University School of Medicine: Yale Stress Center, New Haven, Connecticut, United States
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 212
- Registration Number
- NCT00429273
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 849
- Registration Number
- NCT00389779
- Locations
- 🇺🇸
NEA Clinic, Jonesboro, Arkansas, United States
🇺🇸Cardiovascular Research Inst. of Dallas, Dallas, Texas, United States
🇺🇸Central Cardiology Medical Clinic, Bakersfield, California, United States
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 661
- Registration Number
- NCT00389675
- Locations
- 🇺🇸
Arkansas Primary Care Clinic, PA, Little Rock, Arkansas, United States
🇺🇸Medical Investigators, Inc., Little Rock, Arkansas, United States
🇺🇸St John's Center for Clinical Research, Jacksonville, Florida, United States
Pharmacology of Cognition in Schizotypal Personality Disorder
- Conditions
- Interventions
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 29
- Registration Number
- NCT00353379
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Treatment of Supine Hypertension in Autonomic Failure
- Conditions
- Interventions
- Drug: PlaceboDrug: ClonidineDrug: Nitroglycerin transdermalDrug: Dipyridamole/ Aspirin (Aggrenox)Drug: Desmopressin (DDAVP)Drug: SildenafilDrug: NifedipineDrug: HydralazineDrug: HydrochlorothiazideDrug: BosentanDrug: DiltiazemDrug: EplerenoneDrug: guanfacineDietary Supplement: L-arginineDrug: captoprilDrug: carbidopaDrug: losartanDrug: metoprolol tartrateDrug: nebivolol hydrochlorideDrug: prazosin hydrochlorideDrug: tamsulosin hydrochlorideOther: Head-up tilt.Drug: aliskirenOther: Local heat stress
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 152
- Registration Number
- NCT00223717
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders
- Conditions
- First Posted Date
- 2001-10-24
- Last Posted Date
- 2009-07-28
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 60
- Registration Number
- NCT00025779
- Locations
- 🇺🇸
Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸UCLA Neuropsychiatric Institute, Los Angeles, California, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)
- Conditions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018603
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 35
- Registration Number
- NCT00004376
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.